Literature DB >> 14598869

Glycated hemoglobin standardization--National Glycohemoglobin Standardization Program (NGSP) perspective.

Randie R Little1.   

Abstract

The Diabetes Control and Complications Trial (DCCT) and the United Kingdom Prospective Diabetes Study (UKPDS) demonstrated conclusively that risks for complications in patients with diabetes are directly related to glycemic control, as measured by glycated hemoglobin (GHb). Many diabetes organizations worldwide now recommend GHb targets in terms of DCCT/ UKPDS hemoglobin A1c (HbA1c). However, in 1993 there was a lack of comparability of GHb test results among methods and laboratories that represented a major obstacle to meaningful implementation of specific guidelines for diabetes care. The National Glycohemoglobin Standardization Program (NGSP) was implemented to enable laboratories to report DCCT/UKPDS-traceable GHb/HbA1c results. The number of methods and laboratories certified by the NGSP as traceable to the DCCT has steadily increased. Proficiency testing results show marked improvement in the comparability of GHb results. By the end of 2002, 98% of surveyed laboratories (n = approx. 2000) reported GHb results as HbA1c or equivalent compared to 50% in 1993. Ninety-seven percent of laboratories used an NGSP-certified method. For most certified methods in 2002, between-laboratory CVs were < 5%. For all certified methods in 2002, the mean HbA1c value (%) was within 0.8% HbA1c from the NGSP target at all HbA1c concentrations. The vast majority of laboratories in the US are now reporting results that are traceable to DCCT/UKPDS outcomes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14598869     DOI: 10.1515/CCLM.2003.183

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  60 in total

1.  Use of HbA(1c) in screening for Cuban-Americans with undiagnosed type 2 diabetes.

Authors:  Fatma G Huffman; Joel C Exebio; Gustavo G Zarini; Cristobal Exebio
Journal:  J Immigr Minor Health       Date:  2011-06

2.  Relative inaccuracy of the A1cNow in children with type 1 diabetes.

Authors:  Larry Fox; Mariya Dontchev; Katrina Ruedy; Roy Beck; Craig Kollman; Laurel Messer; Julie Coffey; Darrell Wilson; Elizabeth Doyle; William Tamborlane; Michael Steffes
Journal:  Diabetes Care       Date:  2007-01       Impact factor: 19.112

3.  Hemoglobin A1c predicts diabetes but not cardiovascular disease in nondiabetic women.

Authors:  Aruna D Pradhan; Nader Rifai; Julie E Buring; Paul M Ridker
Journal:  Am J Med       Date:  2007-08       Impact factor: 4.965

4.  Reference materials and commutability.

Authors:  Hubert W Vesper; W Gregory Miller; Gary L Myers
Journal:  Clin Biochem Rev       Date:  2007-11

Review 5.  The clinical use of hemoglobin A1c.

Authors:  Christopher D Saudek; Jessica C Brick
Journal:  J Diabetes Sci Technol       Date:  2009-07-01

6.  Hemoglobin A1c point-of-care assays; a new world with a lot of consequences!

Authors:  Erna Lenters-Westra; Robbert J Slingerland
Journal:  J Diabetes Sci Technol       Date:  2009-05-01

7.  A1cNow InView: a new simple method for office-based glycohemoglobin measurement.

Authors:  Amarbir Mattewal; Saleh Aldasouqi; David Solomon; Ved Gossain; Anthony Koller
Journal:  J Diabetes Sci Technol       Date:  2007-11

8.  Type 2 diabetes self-management social support intervention at the U.S.-Mexico border.

Authors:  Marylyn Morris McEwen; Alice Pasvogel; Gwen Gallegos; Lourdes Barrera
Journal:  Public Health Nurs       Date:  2010 Jul-Aug       Impact factor: 1.462

9.  Glycated haemoglobin A1c for diagnosing diabetes in Chinese population: cross sectional epidemiological survey.

Authors:  Yuqian Bao; Xiaojing Ma; Huating Li; Mi Zhou; Cheng Hu; Haiya Wu; Junling Tang; Xuhong Hou; Kunsan Xiang; Weiping Jia
Journal:  BMJ       Date:  2010-05-17

10.  Comparison of A1C and fasting glucose criteria to diagnose diabetes among U.S. adults.

Authors:  April P Carson; Kristi Reynolds; Vivian A Fonseca; Paul Muntner
Journal:  Diabetes Care       Date:  2009-10-06       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.